• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

US FDA approves Mesoblast’s cell therapy for graft-versus-host disease

by December 19, 2024
written by December 19, 2024

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Mesoblast (NASDAQ:MESO)’s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease (GVHD).

The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy.

The company did not immediately respond to Reuters request for comment on pricing and availability.

GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient’s cells, viewing them as an unfamiliar threat.

Mesenchymal stromal cells are spindle-shaped cells that can have various roles in the body and can differentiate into multiple other types of cells. The cells are isolated from the bone marrow of healthy adult human donors.

The FDA advises the treating physician should monitor the Ryoncil infusion, and discontinue it if there is any evidence of a reaction such as shortness of breath, low blood pressure, fever, or rapid breathing, among others.

Last year, the U.S. health regulator declined to approve the therapy as it required more data to support marketing approval.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Amazon faces possible US strikes as Christmas looms
next post
Nippon Steel, Sojitz to take 49% stake in Champion Iron’s Canada project

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Lawyer group urges overhaul of US bank charter...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Microsoft forecasts slower cloud business growth in second quarter
    • Evolus shares surge on strong Q4 results and upbeat 2025 outlook

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy